Shyu K G, Manor O, Magner M, Yancopoulos G D, Isner J M
Departments of Medicine and Biomedical Research, St Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Boston, MA, USA.
Circulation. 1998 Nov 10;98(19):2081-7. doi: 10.1161/01.cir.98.19.2081.
Angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) have recently been identified as ligands for the endothelial cell-specific Tie2 receptor. Little is known regarding the impact of these Tie2 ligands on postnatal neovascularization. Accordingly, we tested the hypothesis that gene transfer of plasmid DNA encoding Ang1 and Ang2 could modulate collateral vessel development in a rabbit model of hindlimb ischemia.
pAng1* (n=15), pJFE control (no Ang1* insert) (n=9), pAng2 (n=9), pcDNA3 control (no Ang2 insert) (n=10), or saline (n=5) was injected intramuscularly into the rabbit ischemic hindlimb. Collateral vessel development and limb perfusion were assessed before and 30 days after treatment. Calf blood pressure ratio (ischemic to normal hindlimb) was increased 30 days after Ang1* gene transfer versus controls (Ang1*, 0.90+/-0.02; pJFE, 0.76+/-0.05; saline, 0.77+/-0. 03; P<0.05). Angiographic score was higher (P<0.05) in the pAng1* group (0.63+/-0.02) than in the pJFE (0.51+/-0.03) or saline (0. 52+/-0.02) group. Maximal (postpapaverine) blood flow in the ischemic limb was higher (P<0.05) after pAng1* (67.8+/-4.9 mL/min) than pJFE (51.2+/-4.4 mL/min) or saline (52.9+/-4.9 mL/min). Capillary density and capillary/muscle fiber ratio (242+/-12/mm2 and 0.89+/-0.06, respectively) were higher (P<0.01) with pAng1* than pJFE (172+/-11/mm2 and 0.64+/-0.05) or saline (166+/-10/mm2 and 0. 67+/-0.05). Neovascularization was not enhanced with pAng2.
Ang1 but not Ang2 gene transfer produces anatomic and physiological evidence of enhanced collateral vessel formation. Ang1 may modulate neovascularization in adult animals and thus represents a feasible therapeutic strategy for patients with tissue ischemia. The role of Ang2 in postnatal neovascularization remains to be clarified.
血管生成素-1(Ang1)和血管生成素-2(Ang2)最近被确定为内皮细胞特异性Tie2受体的配体。关于这些Tie2配体对出生后新生血管形成的影响,目前了解甚少。因此,我们检验了这样一个假设,即编码Ang1和Ang2的质粒DNA基因转移可以调节兔后肢缺血模型中的侧支血管发育。
将pAng1*(n = 15)、pJFE对照(无Ang1插入片段)(n = 9)、pAng2(n = 9)、pcDNA3对照(无Ang2插入片段)(n = 10)或生理盐水(n = 5)肌肉注射到兔缺血后肢。在治疗前和治疗后30天评估侧支血管发育和肢体灌注情况。与对照组相比,Ang1基因转移后30天,小腿血压比值(缺血后肢与正常后肢)升高(Ang1*,0.90±0.02;pJFE,0.76±0.05;生理盐水,0.77±0.03;P<0.05)。pAng1组的血管造影评分(0.63±0.02)高于pJFE组(0.51±0.03)或生理盐水组(0.52±0.02)(P<0.05)。pAng1组缺血肢体的最大(罂粟碱后)血流量(67.8±4.9 mL/min)高于pJFE组(51.2±4.4 mL/min)或生理盐水组(52.9±4.9 mL/min)(P<0.05)。pAng1*组的毛细血管密度和毛细血管/肌纤维比值(分别为242±12/mm²和0.89±0.06)高于pJFE组(172±11/mm²和0.64±0.05)或生理盐水组(166±10/mm²和0.67±0.05)(P<0.01)。pAng2未增强新生血管形成。
Ang1基因转移而非Ang2基因转移产生了侧支血管形成增强的解剖学和生理学证据。Ang1可能调节成年动物的新生血管形成,因此是组织缺血患者的一种可行治疗策略。Ang2在出生后新生血管形成中的作用仍有待阐明。